NV
Novartis
NVS·NYSEBasel CHFounded 199678,000 employees
Large CappharmaPublicOncologyImmunologyNeurologyCardiology
Platform: Targeted & Cell/Gene
Market Cap
$210B
All Drugs
14
Clinical Trials
25
Failed / Terminated
6
FDA Approved
2
Stock Price & Catalysts (NVS)
Loading NVS stock data...
Drug Pipeline (14 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| NVS-3297 | NVS-3297 | Preclinical | 2 | CDK2 | CLLWM | ||
| Pexatenlimab | NVS-2619 | Phase 1/2 | 2 | GPRC5D | Hemophilia AHCC | ||
| NVS-4076 | NVS-4076 | Preclinical | 1 | TROP-2 | LNWM | ||
| NVS-5439 | NVS-5439 | Preclinical | 1 | BET | SCD | ||
| Lisolucimab | NVS-606 | Approved | 2 | CD20 | Narcolepsy | ||
| NVS-5126 | NVS-5126 | Phase 3 | 2 | SHP2 | CeliacRA | ||
| NVS-1475 | NVS-1475 | Phase 2 | 2 | Menin | MGPBC | ||
| NVS-6974 | NVS-6974 | Preclinical | 1 | CD19 | Parkinson'sET | ||
| Zanuderotide | NVS-8361 | Phase 1/2 | 2 | VEGF | OCDT2D | ||
| NVS-6360 | NVS-6360 | Approved | 4 | CD38 | FTD | ||
| NVS-8902 | NVS-8902 | Preclinical | 2 | TROP-2 | Melanoma | ||
| Rilulemzoparlimab | NVS-5036 | Phase 2/3 | 1 | KRASG12D | Alzheimer's | ||
| Geliderotide | NVS-9238 | NDA/BLA | 2 | IL-17A | CMLPsA | ||
| Adagrazumab | NVS-4548 | Phase 2/3 | 1 | Cl18.2 | Heart Failure |
SEC Filings & Financial Documents
Insider Trading Activity
Fetching insider trading data from SEC EDGAR...
Catalyst Events (21)